211 related articles for article (PubMed ID: 3333018)
1. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
3. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
[TBL] [Abstract][Full Text] [Related]
4. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
5. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
[TBL] [Abstract][Full Text] [Related]
6. [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium].
Nuti R; Righi GA; Turchetti V; Vattimo A
Minerva Med; 1984 Jan; 75(3-4):109-13. PubMed ID: 6366617
[TBL] [Abstract][Full Text] [Related]
7. Preventive treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium. Evaluation of bone histomorphometry in osteoporotics and age matched controls.
Lindholm TS; Nilsson OS; Widhe T; Elmsted E; Eriksson S
Acta Vitaminol Enzymol; 1982; 4(1-2):179-84. PubMed ID: 7124565
[No Abstract] [Full Text] [Related]
8. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Need AG; Morris HA; Hartley TF; Horowitz M; Nordin BE
Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
[TBL] [Abstract][Full Text] [Related]
9. Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial.
Lyritis GP; Androulakis C; Magiasis B; Charalambaki Z; Tsakalakos N
Bone Miner; 1994 Dec; 27(3):209-17. PubMed ID: 7696887
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
[TBL] [Abstract][Full Text] [Related]
11. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
Geusens P
Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
[TBL] [Abstract][Full Text] [Related]
12. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
13. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
Gennari C; AgnusDei D; Gonnelli S; Nardi P
Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
[TBL] [Abstract][Full Text] [Related]
14. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
Need AG; Horowitz M; Bridges A; Morris HA; Nordin BE
Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415
[TBL] [Abstract][Full Text] [Related]
15. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
16. Interim report on treatment of osteoporotic patients with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):232-40. PubMed ID: 709936
[TBL] [Abstract][Full Text] [Related]
17. Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
Lindholm TS; Eriksson S; Lindholm TC
Ital J Orthop Traumatol; 1984 Jun; 10(2):187-201. PubMed ID: 6432736
[TBL] [Abstract][Full Text] [Related]
18. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
Need AG; Horowitz M; Walker CJ; Chatterton BE; Chapman IC; Nordin BE
Bone; 1989; 10(1):3-6. PubMed ID: 2736154
[TBL] [Abstract][Full Text] [Related]
19. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
20. Effects of nandrolone decanoate on bone mass in established osteoporosis.
Passeri M; Pedrazzoni M; Pioli G; Butturini L; Ruys AH; Cortenraad MG
Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
